Effect of CYP3A5*3 polymorphism on Pharmacokinetic drug interaction between tacrolimus and amlodipine

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 5, 2013, Pages 398-405

  Zuo, Xiao Cong ^a   Zhou, Ya Nan ^a   Zhang, Bi Kui ^a,b   Yang, Guo Ping ^a   Cheng, Ze Neng ^a   Yuan, Hong ^a   Ouyang, Dong Sheng ^a   Liu, Shi Kun ^a   Barrett, Jeffrey S ^b   Li, Pei Jiong ^a   Liu, Zhi ^a   Tan, Hong Yi ^a   Guo, Ren ^a   Zhou, Ling Yun ^a   Xie, Yue Liang ^a   Li, Zuo Jun ^a   Li, Jing ^a   Wang, Chun Jiang ^a   Wang, Jiang Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Amlodipine; CYP3A5*3 polymorphism; Drug drug interaction; Pharmacokinetics; Tacrolimus

Indexed keywords

AMLODIPINE; CYTOCHROME P450 3A5; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYP3A5 GENE; DNA POLYMORPHISM; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; VOLUNTEER; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

AMLODIPINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; YOUNG ADULT;

EID: 84886426038     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-148     Document Type: Article

References (51)

1. First, M. R., Neylan, J. F., Rocher, L. L. and Tejani, A.: Hypertension after renal transplantation. J. Am. Soc. Nephrol., 4: S30-S36 (1994).
2. Opelz, G. and Döhler, B.: Improved long-term outcomes after renaltransplantation associated with blood pressure control. Am. J. Transplant., 5: 2725-2731 (2005).
3. Cosio, F. G., Falkenhain, M. E., Pesavento, T. E., Henry, M. L., Elkhammas, E. A., Davies, E. A., Bumgardner, G. L. and Ferguson, R. M.: Relationships between arterial hypertension and renal allograft survival in African-American patients. Am. J. Kidney Dis., 29: 419-427 (1997).
4. Mangray, M. and Vella, J. P.: Hypertension after kidney transplant. Am. J. Kidney Dis., 57: 331-341 (2011).
5. Leenen, F. H., Coletta, E. and Davies, R. A.: Prevention of renal dysfunction and hypertension by amlodipine after heart transplant. Am. J. Cardiol., 100: 531-535 (2007).
6. First, M. R.: Tacrolimus based immunosuppression. J. Nephrol., 17: S25-31 (2004).
7. Staatz, C. E. and Tett, S. E.: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet., 43: 623-653 (2004).
8. Iwasaki, K.: Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab. Pharmacokinet., 22: 328-335 (2007).
9. Staatz, C. E., Goodman, L. K. and Tett, S. E.: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet., 49: 141-175 (2010).
10. Renders, L., Frisman, M., Ufer, M., Mosyagin, I., Haenisch, S., Ott, U., Caliebe, A., Dechant, M., Braun, F., et al.: CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin. Pharmacol. Ther., 81: 228-234 (2007).
11. Rong, G., Jing, L., Deng-Qing, L., Hong-Shan, Z., Shai-Hong, Z. and Xin-Min, N.: Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant. Proc., 42: 3455-3458 (2010).
12. Kuzuya, T., Kobayashi, T., Moriyama, N., Nagasaka, T., Yokoyama, I., Uchida, K., Nakao, A. and Nabeshima, T.: Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation, 76: 865-868 (2003).
13. Pesavento, T. E., Jones, P. A., Julian, B. A. and Curtis, J. J.: Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J. Am. Soc. Nephrol., 7: 831-835 (1996).
14. Guengerich, F. P., Brian, W. R., Iwasaki, M., Sari, M. A., Bäärnhielm, C. and Berntsson, P.: Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J. Med. Chem., 34: 1838-1844 (1991).
15. Walker, D. K., Humphrey, M. J. and Smith, D. A.: Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica, 24: 243-250 (1994).
16. Fukuen, S., Fukuda, T., Maune, H., Ikenaga, Y., Yamamoto, I., Inaba, T. and Azuma, J.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics, 12: 331-334 (2002).
17. Ware, N. and Macphee, I. A.: Current progress in pharm acogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr. Opin. Mol. Ther., 12: 270-283 (2010).
18. Tang, H. L., Xie, H. G., Yao, Y. and Hu, Y. F.: Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet. Genomics, 21: 713-720 (2011).
19. Emoto, C. and Iwasaki, K.: Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica, 36: 219-233 (2006).
20. Zhang, G. M., Li, L., Chen, W. Q., Bi, S. S., Liu, X., Zhang, X. L. and Lu, W.: Population pharmacokinetic study of tacrolimus in China renal transplant patients. Yao Xue Xue Bao., 43: 695-701 (2008).
21. Jones, T. E. and Morris, R. G.: Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin. Pharmacokinet., 41: 381-388 (2002).
22. Butani, L., Berg, G. and Makker, S. P.: Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. Transplantation, 73: 159-160 (2002).
23. Seifeldin, R. A., Marcos-Alvarez, A., Gordon, F. D., Lewis, W. D. and Jenkins, R. L.: Nifedipine interaction with tacrolimus in liver transplant recipients. Ann. Pharmacother., 31: 571-575 (1997).
24. Hooper, D. K., Carle, A. C., Schuchter, J. and Goebel, J.: Interaction between tacrolimus and intravenous nicardipine in the treatment of postkidney transplant hypertension at pediatric hospitals. Pediatr. Transplant., 15: 88-95 (2011).
25. Hooper, D. K., Fukuda, T., Gardiner, R., Logan, B., Roy-Chaudhury, A., Kirby, C. L., Vinks, A. A. and Goebel, J.: Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. Transplantation, 93: 806-812 (2012).
26. Toupance, O., Lavaud, S., Canivet, E., Bernaud, C., Hotton, J. M. and Chanard, J.: Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension, 24: 297-300 (1994).
27. Zhou, Y. N., Zhang, B. K., Li, J., Zuo, X. C., Yuan, H., Yang, G. P., Cheng, Z. N., Liu, Z., Li, P. J., et al.: Effect of amlodipine on the pharmacokinetics of tacrolimus in rats. Xenobiotica, 43: 699-704 (2013).
28. Li, D., Zhang, G. L., Lou, Y. Q., Li, Q., Wang, X. and Bu, X. Y.: Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J. Clin. Pharm. Ther., 32: 89-95 (2007).
29. Li, D., Gui, R., Li, J. and Nie, X.: Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant. Proc., 38: 2850-2852 (2006).
30. Tsuchiya, N., Satoh, S., Tada, H., Li, Z., Ohyama, C., Sato, K., Suzuki, T., Habuchi, T. and Kato, T.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 78: 1182-1187 (2004).
31. Katoh, M., Nakajima, M., Yamazaki, H. and Yokoi, T.: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoproteinmediated transport: comparison with the effects on CYP3A4. Pharm. Res., 17: 1189-1197 (2000).
32. Yong Chung, J., Jung Lee, Y., Bok Jang, S., Ahyoung Lim, L., Soo Park, M. and Hwan Kim, K.: CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther. Drug Monit., 32: 67-72 (2010).
33. Hesselink, D. A., van Gelder, T., van Schaik, R. H., Balk, A. H., van der Heiden, I. P., van Dam, T., van der Werf, M., Weimar, W. and Mathot, R. A.: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther., 76: 545-556 (2004).
34. Ball, S. E., Scatina, J., Kao, J., Ferron, G. M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P. J., et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5A promoter region of CYP3A4. Clin. Pharmacol. Ther., 66: 288-294 (1999).
35. Miura, M., Satoh, S., Kagaya, H., Saito, M., Numakura, K., Tsuchiya, N. and Habuchi, T.: Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics, 12: 977-984 (2011).
36. Zuo, X.-C., Ng, C. M., Barrett, J. S., Luo, A.-J., Zhang, B.-K., Deng, C.-H., Xi, L.-Y., Cheng, K., Ming, Y.-Z., et al.: Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet. Genomics, 23: 251-261 (2013).
37. de Jonge, H., de Loor, H., Verbeke, K., Vanrenterghem, Y. and Kuypers, D. R.: In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin. Pharmacol. Ther., 92: 366-375 (2012).
38. Plummer, S. J., Conti, D. V., Paris, P. L., Curran, A. P., Casey, G. and Witte, J. S.: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 12: 928-932 (2003).
39. Leroy, S., Isapof, A., Fargue, S., Fakhoury, M., Bensman, A., Deschênes, G., Jacqz-Aigrain, E. and Ulinski, T.: Tacrolimus nephrotoxicity: beware of the association of diarrhrea, drug interaction and pharmacogenetics. Pediatr. Nephrol., 25: 965-969 (2010).
40. Zhao, W., Baudouin, V., Fakhoury, M., Storme, T., Deschênes, G. and Jacqz-Aigrain, E.: Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. Transplantation, 93: e29-e30 (2012).
41. Lee, J. E., van Heeswijk, R., Alves, K., Smith, F. and Garg, V.: Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob. Agents Chemother., 55: 4569-4574 (2011).
42. Glesby, M. J., Aberg, J. A., Kendall, M. A., Fichtenbaum, C. J., Hafner, R., Hall, S., Grosskopf, N., Zolopa, A. R. and Gerber, J. G.: Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin. Pharmacol. Ther., 78: 143-153 (2005).
43. Kim, K. A., Park, P. W., Lee, O. J., Choi, S. H., Min, B. H., Shin, K. H., Chun, B. G., Shin, J. G. and Park, J. Y.: Effects of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin. Pharmacol. Ther., 80: 646-656 (2006).
44. Park, K. W., Kang, J., Park, J. J., Yang, H. M., Lee, H. Y., Kang, H. J., Koo, B. K., Oh, B. H., Park, Y. B., et al.: Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart, 98: 1366-1372 (2012).
45. Josefsson, M., Zackrisson, A. L. and Ahlner, J.: Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur. J. Clin. Pharmacol., 51: 189-193 (1996).
46. Sasaki, M., Maeda, A. and Fujimura, A.: Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients. Eur. J. Clin. Pharmacol., 57: 85-86 (2001).
47. Lecointre, K., Furlan, V. and Taburet, A.: In vitro effects of tacrolimus on human cytochrome P450. Fundam. Clin. Pharmacol., 16: 455-460 (2002).
48. de Jonge, H., de Loor, H., Verbeke, K., Vanrenterghem, Y. and Kuypers, D. R.: In vivo CYP3A activity is significantly lower in cyclosporinetreated as compared with tacrolimus-treated renal allograft recipients. Clin. Pharmacol. Ther., 90: 414-422 (2011).
49. Iwasaki, K., Shiraga, T., Matsuda, H., Noda, K., Yamazoe, Y., Nagata, K., Yasumori, T., Ozawa, S., Shimada, M., et al.: Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixedfunction oxidase system in the rat: comparative study with ciclosporin. Arzneimettelforschung, 42: 340-344 (1992).
50. Hauser, I. A., Koziolek, M., Hopfer, U. and Thévenod, F.: Therapeutic concentrations of cyclosporine A, but not FK506, increase p-glycoprotein expression in endothelial and renal tubule cells. Kidney Int., 54: 1139-1149 (1998).
51. Christians, U., Jacobsen, W., Benet, L. Z. and Lampen, A.: Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet., 41: 813-851 (2002).